Life Technologies Launches Two Ion AmpliSeq™ Community Panel Designs: Ion AmpliSeq™ BRCA1 and BRCA2 Panel and the Ion

  Life Technologies Launches Two Ion AmpliSeq™ Community Panel Designs: Ion
  AmpliSeq™ BRCA1 and BRCA2 Panel and the Ion AmpliSeq™ Colon & Lung Cancer
                                    Panel

PR Newswire

CARLSBAD, Calif., April 2, 2013

CARLSBAD, Calif., April 2, 2013 /PRNewswire/ -- Life Technologies Corporation
(NASDAQ: LIFE) today announced it launched two Ion AmpliSeq™ Community Panels:
the Ion AmpliSeq™ BRCA1 and BRCA2 Panel design and the Ion AmpliSeq™ Colon and
Lung Cancer Panel design.

The BRCA panel analyzes the coding regions of the tumor suppressor genes BRCA1
and BRCA2, which have been implicated in hereditary breast and ovarian
cancers. The colon and lung panel analyzes more than 500 mutations in 22
associated genes, using the power and simplicity of the established Ion
AmpliSeq™ technology. Significant and ongoing improvements with Ion sequencing
have enabled these Ion AmpliSeq™ panels to accurately call all variants of
interest, including those within difficult sequence contexts.

Life Technologies is hosting three talks at the American Association of Cancer
Research (AACR) on Saturday, April 6 about the use of Ion AmpliSeq™ panels in
clinical research:

  oNicola Normanno, MD, Centro Ricerche Oncologiche di Mercogliano, Avellino,
    Italy, will discuss the development of the Ion AmpliSeq™ Lung and Colon
    Community Panel and the collaborative efforts of the eight-member European
    consortia.
  oMarina Nikiforova, MD, University of Pittsburgh Medical Center,
    Pittsburgh, Pennsylvania will discuss using the Ion AmpliSeq™ RNA Panels
    for detection of chromosomal rearrangements in thyroid cancer research.
  oSix panelists will discuss implementing Ion AmpliSeq™ Cancer Gene Panels
    on the Ion PGM™ System for clinical research.

Ion AmpliSeq™ Community Panels are developed by leading scientists who draw on
their expertise in a specific disease area to develop the panels. They verify
the content using samples that were previously screened using orthogonal
technologies. The panel designs are then made available to the entire
scientific community on ampliseq.com.

Ion AmpliSeq™ Community Panels are built on the same breakthrough technology
that powers the Ion AmpliSeq™ Ready-to-Use Panels and the Ion AmpliSeq™ Custom
Panels. Like all Ion AmpliSeq™ technology, the community panels require just
10 ng of DNA input per primer pool, about 25-fold less than alternative gene
panel approaches.The Ion AmpliSeq™ workflow is a simple PCR reaction coupled
with rapid Ion semiconductor sequencing, enabling researchers to go from DNA
to results in less than 24 hours.

The Ion AmpliSeq™ BRCA1 and BRCA2 panels were developed by Drs. Marjolijn
Ligtenberg and Arjen Mensenkamp from Radboud University Nijmegen Medical
Centre, The Netherlands, and with Drs. Jose Carlos Machado and Jose Luis Costa
from The Institute of Molecular Pathology and Immunology of the University of
Porto. In addition to these leading researchers in the field, a global
consortium will further test the panel, with plans to validate and implement
it in their labs.

"Ion AmpliSeq™ technology has allowed us to substantially improve the
turnaround time and cost of sequencing these important genes," said Costa.
"The methodology proved robust enough to call even difficult mutations,
includinglong homopolymers, in these two genes."

"The Ion AmpliSeq™ BRCA panel enabled us to develop a quick and easy
high-throughput workflow, with minimal hands-on time," said Mensenkamp. "It is
an accurate solution—of the 65 samples tested to date, we detected all
expected mutations."

Life Technologies announced the community panel program in November with the
first Ion AmpliSeq™ Community Panel—the Ion AmpliSeq™ Colon and Lung Cancer
Panel design. The panel analyzes more than 500 mutations in a single-tube
assay that requires just 10 ng of DNA input per primer pool, about 25-fold
less than alternative gene panel approaches. The Ion AmpliSeq™ workflow is as
simple as a PCR reaction and can be completed in as few as 3.5 hours
turnaround time. That panel design is now available on ampliseq.com.

"The Ion AmpliSeq™ Colon and Lung Cancer panel design permits you to describe
a cancer according to the molecular subpopulation that compose the lesion and
this is impossible to do with previous methods," said Dr. Aldo Scarpa,
Director, Dept. of Pathology andARC-NET Research Centre for Applied Research
on Cancer, University of Verona, Italy.

Eight institutions – dubbed the OncoNetwork – participated in the development
of the panel: Centro Ricerche Oncologiche Mercogliano, Italy; Leiter Genetik /
Molekularbiologie Viollier AG, Switzerland; University of Warwick, UK;
Institut Gustave Roussy France; Radboud UniversityNijmegen Medical Centre,
The Netherlands; Universite Paris Descartes Centre, Universitaire des
Saints-Peres, France; St James' Hospital, Dublin EIRE and ARC-NET Research
Center, University of Verona, Italy.

The Ion AmpliSeq™ panels referenced are For Research Use Only. Not for use in
diagnostic procedures.

About Life Technologies

Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology
company that is committed to providing the most innovative products and
services to leading customers in the fields of scientific research, genetic
analysis and applied sciences. With a presence in more than 180 countries, the
company's portfolio of 50,000 end-to-end solutions is secured by more than
5,000 patents and licenses that span the entire biological spectrum --
scientific exploration, molecular diagnostics, 21^stcentury forensics,
regenerative medicine and agricultural research. Life Technologies has
approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by Life Technologies with the Securities and Exchange
Commission. Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Wes Conard
415-385-4455
wes.conard@lifetech.com

SOURCE Life Technologies Corporation

Website: http://www.lifetechnologies.com